NCT04287608 - Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2023

Conditions

ConjunctivitisAtopic Dermatitis

Interventions

DRUG

dupilumab

No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.

Trial Locations (15)

10029

Regeneron Study Site, New York

11021

Regeneron Study Site, Great Neck

15213

Regeneron Study Site, Pittsburgh

19104

Regeneron Study Site, Philadelphia

21205

Regeneron Study Site, Baltimore

33136

Regeneron Study Site, Miami

38163

Regeneron Study Site, Memphis

70112

Regeneron Study Site, New Orleans

77030

Regeneron Study Site, Houston

91105

Regeneron Study Site, Pasadena

92697

Regeneron Study Site, Irvine

94303

Regeneron Study Site, Palo Alto

97239

Regeneron Study Site, Portland

02114

Regeneron Study Site, Boston

75390-8575

Regeneron Study Site, Dallas